Publicaciones científicas

Intralesional corticosteroid injection for the treatment of hidradenitis suppurativa: A multicentre retrospective clinical study

12-ago-2019 | Revista: The Journal of Dermatological Treatment

García-Martínez FJ (1), Vilarrasa Rull E (2), Salgado-Boquete L (3), Martorell A (4,) Pascual JC (5), Hernández-Martín A (6,) Silvente C (7), Ciudad-Blanco C (8), de Andrés E (9), Alfageme-Roldán F (10).

(1a) Dermatology Department, Clínica Universidad de Navarra , Madrid ; Hidradenitis Suppurativa and Cutaneous Ultrasound Unit, Hospital Universitario del Sureste , Arganda del Rey , Madrid , Spain.
(2b) Dermatology Department, Hospital de la Santa Creu i Sant Pau , Barcelona , España.
(3c) Dermatology Department, Complexo Hospitalario de Pontevedra , Pontevedra , Spain.
(4d) Dermatology Department, Hospital de Manises , Valencia , Spain.
(5e) Dermatology Department, Hospital General de Alicante , Alicante , Spain.
(6f) Dermatology Department, Hospital Infantil Universitario Niño Jesús , Madrid , Spain.
(7g) Dermatology Department, Hospital Infanta Leonor , Madrid , Spain.
(8h) Dermatology Department, Hospital General Universitario Gregorio Marañón , Madrid , Spain.
(9i) Preventive Medicine Department, Universidad Jaume I de Castellón , Castellón , Spain.
(10j) Dermatology Department, Hospital Universitario Puerta de Hierro , Majadahonda , Madrid , Spain.


Hidradenitis suppurativa (HS) is a chronic inflammatory disease of the follicular unit characterized by recurrent, painful, skin lesions including inflammatory nodules, abscesses, tunnels and mutilating scarring. Intralesional corticosteroids injection (ICI) for HS has received little attention in scientific literature. We evaluate the clinical response of ICI in acute and chronic HS lesions and aim to identify new applications of ultrasound assisted procedures in HS management.


An observational, retrospective, multicenter study of HS patients treated with ICI was conducted from January 1 to August 1, 2015 We collected 98 HS patients. 135 individual lesions were infiltrated, including non-inflammatory nodules, inflammatory nodules abscesses and fistulous tracts.


Complete response was reached in 95 lesions (70.37%), 34 showed partial response (25.19%) and 6 (4.44%) were non-response. 105 individual lesions underwent sonographic scan before ICI.


Clinical experience supported the use of ICI for individual lesions. Our results showed that ICI is a useful treatment to control in acute and recalcitrant HS lesions. Response rates improves significantly if lesions are previously evaluated with HFUS.

CITA DEL ARTÍCULO  J Dermatolog Treat. 2019 Aug 12:1-19. doi: 10.1080/09546634.2019.1655524